Seres Therapeutics
MCRB
NASDAQ
IPO2015
about MCRB
Seres Therapeutics is a biotechnology company that develops microbiome-based therapies to treat serious infections and inflammatory diseases, including Clostridioides difficile infection and ulcerative colitis.
| type | open | high | low |
market cap |
volume |
|---|---|---|---|---|---|
| stock | $10.04 | $10.96 | $8.00 | $127.47M | 688.24K |
| eps |
price to earnings |
price to sales |
operating margin |
profit margin |
yield |
| +$0.94 | 2.74 | 205.42 | -6403.70% | 2337.32% | 0% |